Microbot Medical Q2 2026: First Commercial Sales Arrive, but Losses Deepen and a Patent Deal Expands the Pipeline
MBOT sits 20% above its 52-week low of $1.6.
Summary
Microbot Medical's Q2 2026 10-Q reveals first commercial revenues of $241K from its LIBERTY robotic system, but losses widened to $5.6M as commercialization costs surged. The company also acquired VasoStat hemostasis patents in a royalty-only deal.
Key Events · Earnings and Guidance · MBOT
-
First Commercial Revenues
Revenue from LIBERTY robotic system sales reached $241K in Q2 2026 and $346K for the first half, marking the company's transition to commercial operations.
-
Widening Losses
A surge in sales, general and administrative expenses to $3.7M from $1.6M—driven by the build-out of the commercial team—pushed the net loss to $5.6M in Q2 2026, compared with $3.5M in Q2 2025.
-
Cash Burn and Runway
Operating cash burn totaled $10.0M in H1 2026, but with $67.4M in cash and marketable securities as of June 30, 2026, the company has over 12 months of runway.
-
ATM Program Update
A new prospectus supplement filed on April 10, 2026 allows the sale of up to $39.2M of common stock through the ATM program; only $17K was sold in Q2.
Analysis · MBOT · Industrial Applications And Services
The first full quarter of commercial sales for Microbot Medical's LIBERTY robotic system brought in $241K in revenue, yet costs far outpaced sales, pushing the net loss to $5.6M—nearly double the prior-year quarter. Operations consumed $10M in cash during the first half, though the company still holds $67.4M in cash and securities. A subsequent patent acquisition for a hemostasis device adds a new product line with no upfront cash cost, only future royalties. While the revenue milestone and strong cash position provide runway, the widening losses and heavy cash burn remain the key concerns.
At the time of this filing, MBOT was trading at $1.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $130M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.